Skip to main content
. 2022 Sep 13;3:932530. doi: 10.3389/fpain.2022.932530

Figure 5.

Figure 5

Intrathecal administration of NLRP3 antagonist MCC950 reverses EAE-related pain in Sprague-Dawley (SD) rats. Sprague-Dawley (SD) rats were baselined (BL) for mechanical withdrawal thresholds via the von Frey test, followed by intradermal low-dose (8 μg) myelin oligodendrocyte glycoprotein (MOG). MCC950 (0, 0.01, 0.1, 1 mg) was intrathecally administered (see dotted line/arrow indicating time of drug delivery), and allodynia was assessed prior to and at 3 and 24 h post-MCC950 delivery. Intrathecal administration of all doses of 0.01, 0.1, and 1 mg MCC950 on day 23 post-MOG significantly reversed EAE-induced mechanical allodynia at 3 h but not 24 h post-administration. Main effects of day [F(5, 70) = 75.78; p < 0.01], MCC950 dose [F(3, 14) = 4.15; p < 0.05], and interaction between day and MCC950 dose [F(15, 70) = 2.83; p < 0.01]. N = 4–5/group. Post-hocs: *** indicates significant differences between saline control and 0.01 mg MCC950, ## indicates significant differences between saline control and 0.1 mg, and ∧∧∧∧ indicates significant differences between saline control and 1 mg.